PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGINGRELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

摘要

Pyridinium derivatives (I) and their salts are new. Pyridinium derivatives of formula (I) and their salts are new: [Image] R 1R 4R 5 or N(R 7)N(R 7)R 9; R 4N(R 7)R 6O, N(R 7)R 6N(R 7), OR 6O, or OR 6N(R 7); R 6alkyl; R 5alkyl, aryl, heteroaryl, COR 7, SO 2R 7, C(S)NHR 7, C(NH)NHR 7, C(O)R 1 0, C(O)NHR 7, or N(R 7)N=C(R 7)R 1 0; R 7,R 1 0H, alkyl, aryl or heteroaryl (provided that the N of the heteroaryl, when present, of R 1 0 is optionally quarternized with compounds such as X-CH 2C(O)R 3; R 2F, Cl, Br, I, OR 7, NO 2, alkyl, aryl, heteroaryl, formyl, acyl, C(O)NR 7R 1 0, CO 2R 7, NR 7R 1 0, N=C(R 7)R 1 0, SR 7, SO 2NH 2, SO 2-alkyl or SO 2-aryl; m : 0-2; R 3R 7, OR 7, NR 7R 1 0, N=C(R 7)R 1 0, N(R 7)NR 7R 1 0, N(R 7)N=C(R 7)R 1 0 or CH(R 7)C(O)R 8; R 8R 7, OR 7 or NR 7R 1 0; R 9H, alkyl, aryl, heteroaryl, C(O)R 1 0, SO 2R 1 0, C(S)NHR 1 0, C(NH)NHR 1 0, or C(O)NHR 1 0; and X : halide, acetate, perchlorate, sulfate, oxalate, citrate, tosylate, maleate, mesylate, carbonate, sulfite, phosphoric hydrogen, phosphonate, phosphate, BF 4 - or PF 6 - (provided that when 2 alkyl groups are present on the same C or N, they may link together to form a cycloalkyl group). Independent claims are also included for: (a) a process for the preparation of (I) comprising preparing the properly substituted pyridine derivative followed by quarternization; (b) the use of (I) in the manufacture of a medicament for diabetic complications and aging-related diseases including kidney disease, nerve damage, retinopathy, artherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions, discoloration of teeth and other organ dysfunctions; (c) a method for treating a diabetic patient by breaking preformed advanced glycation end products (AGE) comprising administration of (I) either singly or in combination with another drug. ACTIVITY : Antidiabetic; nephrotropic; neuroprotective; ophthalmological; antiarteriosclerotic; dermatological; dental. Tests were performed to study the efficacy of (I) in the inhibition of advanced glycation end products (AGE) breaker activity. Bovine serum albumin (160 mg/ml) and glucose sugar (1.6 M) were dissolved in phosphate buffered saline. Sodium azide was added at 0.2 % concentration. The solution was filtered and kept for aging at 37 [deg] C for 16 weeks. After 16 weeks the solution was dialyzed against PBS, aliquoted and stored at -20 [deg] C. The AGE breaking activity of N,N'-bis[3-carbonyl-1-(2-phenyl-2-oxoethyl)pyridinium]hydrazine dibromide (Ia) at 5 mM was tested, and found to be 13 %. MECHANISM OF ACTION : None given.